Fate Therapeutics (Fate Therapeutics) Effective Interest Rate on Debt % : 0.00% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Fate Therapeutics Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Fate Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Dec. 2023 was $0.00 Mil. Fate Therapeutics's average total debt for the quarter that ended in Dec. 2023 was $104.25 Mil. Therefore, Fate Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 was 0.00%.

Fate Therapeutics Effective Interest Rate on Debt % Historical Data

The historical data trend for Fate Therapeutics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fate Therapeutics Effective Interest Rate on Debt % Chart

Fate Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

8.38

Fate Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Fate Therapeutics's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Fate Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fate Therapeutics's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fate Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Fate Therapeutics's Effective Interest Rate on Debt % falls into.

Fate Therapeutics Effective Interest Rate on Debt % Calculation

Fate Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Dec. 2022 )	+	Total Debt (A: Dec. 2023 ))	/ count )
=	-1 * 0	/	( (109.338	+	103.536)	/ 2 )
=	-1 * 0	/	106.437
=	0.00 %

where

	Total Debt (A: Dec. 2022 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	103.71	+	5.628
=	109.338

	Total Debt (A: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	97.36	+	6.176
=	103.536

Fate Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Sep. 2023 )	+	Total Debt (Q: Dec. 2023 ))	/ count )
=	-1 * 0	/	( (104.954	+	103.536)	/ 2 )
=	-1 * 0	/	104.245
=	0.00 %

where

	Total Debt (Q: Sep. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	98.977	+	5.977
=	104.954

	Total Debt (Q: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	97.36	+	6.176
=	103.536

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Fate Therapeutics (NAS:FATE) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Fate Therapeutics Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Fate Therapeutics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

Fate Therapeutics (Fate Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fate Therapeutics Inc (NAS:FATE) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

F6T:Germany F6T:Germany

Address

12278 Scripps Summit Drive, San Diego, CA, USA, 92131

Website

https://www.fatetherapeutics.com

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Executives

J Scott Wolchko	director, officer: President and CEO	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Dulac Edward J Iii	officer: Chief Financial Officer	FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
Bahram Valamehr	officer: Chief Development Officer	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, STE 200, SAN DIEGO CA 92121
Cindy Tahl	officer: See Remarks	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, STE 200, SAN DIEGO CA 92121
Redmile Group, Llc	director, 10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Yuan Xu	director	C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Brian T. Powl	officer: Chief Commercial Officer	C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO CA 92131
Yu-waye Chu	officer: See Remarks	FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
John Mendlein	director
Mark Plavsic	officer: Chief Technical Officer	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
Shefali Agarwal	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Karin Jooss	director	C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Timothy P Coughlin	director	339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075
Robert Hershberg	director	3005 FIRST AVENUE, SEATTLE WA 98121
Robert S Epstein	director